Mills GB - Search Results

1

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Vaughan S, et al. Among authors: mills gb. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144. Nat Rev Cancer. 2011. PMID: 21941283 Free PMC article.

2

Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.

Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A. Hurteau J, et al. Cancer. 1994 Jul 1;74(1):93-9. doi: 10.1002/1097-0142(19940701)74:1<93::aid-cncr2820740117>3.0.co;2-p. Cancer. 1994. PMID: 8004589

3

Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression.

Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC Jr. Wiener JR, et al. Among authors: mills gb. Gynecol Oncol. 1996 May;61(2):233-40. doi: 10.1006/gyno.1996.0131. Gynecol Oncol. 1996. PMID: 8626139

4

Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.

Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB. Hurteau JA, et al. Among authors: mills gb. Cancer. 1995 Nov 1;76(9):1615-20. doi: 10.1002/1097-0142(19951101)76:9<1615::aid-cncr2820760918>3.0.co;2-g. Cancer. 1995. PMID: 8635066 Clinical Trial.

5

Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.

Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC Jr, Ostrowski MC. Patton SE, et al. Among authors: mills gb. Cancer Res. 1998 May 15;58(10):2253-9. Cancer Res. 1998. PMID: 9605774

6

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.

Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC Jr. Xu FJ, et al. Among authors: mills gb. Clin Cancer Res. 1997 Sep;3(9):1629-34. Clin Cancer Res. 1997. PMID: 9815853

7

Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model.

Pusztai L, Siddik ZH, Mills GB, Bast RC Jr. Pusztai L, et al. Among authors: mills gb. Acta Oncol. 1998;37(7-8):629-40. doi: 10.1080/028418698429964. Acta Oncol. 1998. PMID: 10050979 Review.

8

Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).

Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. Hagopian GS, et al. Among authors: mills gb. Clin Cancer Res. 1999 Mar;5(3):655-63. Clin Cancer Res. 1999. PMID: 10100719

9

CA 125: the past and the future.

Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. Bast RC Jr, et al. Among authors: mills gb. Int J Biol Markers. 1998 Oct-Dec;13(4):179-87. doi: 10.1177/172460089801300402. Int J Biol Markers. 1998. PMID: 10228898 Review.

10

Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?

Mills GB, Schmandt R, Gershenson D, Bast RC. Mills GB, et al. Clin Cancer Res. 1999 Sep;5(9):2286-8. Clin Cancer Res. 1999. PMID: 10499594 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,137 results

Search Page